(Information sent by the signatory company)
SHANGHAI, Feb. 24, 2023 /PRNewswire/ -- ChemPartner today announced the appointment of Lilly Xu, Ph.D. as the president of Shanghai ChemPartner.
Dr. Xu is an experienced manager with a strong portfolio of successes. She joined ChemPartner in 2017 to lead Strategic Drug Discovery Services as Senior Vice President and Head of DMPK and Exploratory Toxicology. Prior to joining ChemPartner, Dr. Xu held various positions with US pharmaceutical and biotech companies including Amgen and Sanofi US. In addition, she was the Director of the Predictive ADMET Center at Sanofi US and has a Green Belt in Lean 6 Sigma. Dr. Xu received her Ph.D. in molecular and cellular biology from Saint Louis University, Missouri. During her tenure in academia, she pioneered the use of human and animal hepatocytes in drug metabolism and drug-drug interactions.
"We are confident that Dr. Xu can leverage her deep understanding of drug discovery and proven experience in organizational leadership to accelerate the growth of Shanghai ChemPartner," said Xianwei Zeng, Chairman and CEO of ChemPartner.
Livia Legg, Chief Scientific Officer of Shanghai ChemPartner and GM of ChemPartner Corporation (United States) and ChemPartner Europe, added: "I have had the pleasure of working with Dr. Xu for the past six years at ChemPartner. She is a talented leader with great integrity. Dr. Xu cares deeply about her colleagues and clients, and her passion, commitment, and drive are evident."
As the world's leading CRO and CDMO, ChemPartner provides integrated life sciences services for drug discovery and development with expertise in discovery chemistry, biology, pharmacology, DMPK, exploratory toxicology, biologics discovery and development, and biologics manufacturing. ChemPartner is uniquely positioned to be not just a CRO, but a true biopharmaceutical alliance partner. The company's mission is to provide R&D services of the highest quality and help clients advance their projects in a timely and cost-effective manner. ChemPartner is strategically aligned with and dedicated to driving the innovative research initiatives of pharmaceutical and biotechnology companies around the world.
"I am delighted to assume this new leadership role at ChemPartner and work closely with our highly experienced executive team to achieve our company's vision and goals. My experience in drug discovery and development operations, combined with the experience of the team, provides ChemPartner's global customers with the skills and competence they want and need," said Dr. Xu. I am excited about ChemPartner's unique service offering, as well as the potential for additional growth."
ChemPartner is the holding company of Shanghai ChemPartner and provides a broad range of drug discovery, development and manufacturing services, including chemistry and biologics discovery, biology, pharmacology, DMPK and toxicology, as well as CDMO biologics development and manufacturing services. . Shanghai ChemPartner serves a diverse customer base around the world, with laboratories, sales offices, and representatives in the United States, Europe, China, and Japan.
Livia Legg, MS, Business Manager
Photo - https://mma.prnewswire.com/media/2008210...
Photo - https://mma.prnewswire.com/media/2008211...
View original content: https://www.prnewswire.com/news-releases/la-doctora-lilly-xu-es-nombrada-presidenta-de-shanghai-chempartner-301755531.html